Intercept Announces Failure of Phase III Clinical Trial Study of Obeticholic Acid
ADC评论
October 3, 2022
On September 30, Intercept announced that the phase III REVERSE study of obeticholic acid (Ocaliva, obeticholic acid, OCA) in the treatment of nonalcoholic steatohepatitis (NASH)-related
